Thursday, February 02, 2017 10:03:08 AM
NOTE: This article discusses research by Sanofi, Inovio and GeoVax, (GOVX @ .06, Tiny $3.2M market cap) Great DD here.
PlasmaVoice: Feb.,2017
GeoVax’s approach to Zika vaccine development uses a recombinant Modified Vaccinia Ankara virus (MVA) viral vector to produce virus-like particles (VLPs) in the person being vaccinated. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating the immune system to recognize, prevent, and control the target infection.
In human clinical trials of the company’s HIV vaccines (which have completed Phase IIa trials), GeoVax has demonstrated that MVA-VLPs are safe and can elicit strong and durable antibody and cellular immune responses to fight HIV infections.
For the Zika virus (ZIKV), GeoVax is working in collaborations with the University of Georgia Research Foundation and the Centers for Disease Control.
With the CDC, the company has developed an animal model and has performed mouse efficacy studies. ZIKV and reagents will be supplied by the University of Texas Medical Branch.
MVA has been safely administered to 120,000 humans in Germany in a campaign for eradication of smallpox in the 60s and later as a vector for delivery of other vaccines including HIV, malaria and tuberculosis, says Farshad Guirakhoo, Ph.D., chief scientific officer of GeoVax.
“Our Zika vaccine has shown 100% protection against death in a mouse model after a single inoculation,” he says. “MVA has been adapted to replicate in chickens, so when it is used in humans as a vector for delivery of other vaccine target antigens, the virus can’t reproduce infectious progeny to spread in the host, making it highly safe for people.”
Unlike other companies that are using viruses to create a Zika vaccine, Inovio is developing a DNA-based monoclonal antibody. This DNA-based monoclonal antibody technology has the potential to lead to products that can be designed and manufactured on a large scale using common fermentation technology. Inovio’s DNA-based immunotherapy platform can target both immediate therapy through delivery of dMAb products as well as long-term immunity via DNA vaccination.
Link:
http://www.pharmavoice.com/article/2017-2-zika-research/
Recent INO News
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:01:55 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 11/01/2023 12:00:00 PM
- INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 • PR Newswire (US) • 10/26/2023 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM